Skip to content
Sanofi logo

Sanofi India

SANOFI NSE
₹3,450.80 +69.20 (+2.05%)
P/E
24.51
View as Markdown
MCP
Close 4 Nov 2026 ₹3,450.80 −1,295.60 −27.3% 1Y
Start ₹4,746.40

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
57.50%
Debt to Equity
0.02
EPS (TTM)
₹140.78
Book Value
₹358.68
Market Cap
—
P/E (TTM)
24.51
P/B
9.62
ROE
43.00%
Dividend Yield
2.22%
EBITDA
₹507 Cr
52W High
₹4,775.00
52W Low
₹2,758.20
Day Range
₹3,363.40 – ₹3,465.00
Volume
77,582

Peer Comparison

Healthcare › Pharmaceuticals

Sanofi peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Sanofi (this company)
₹3,450.8024.51₹7,821 Cr9.622.22%43.00%57.50%₹1,805 Cr₹325 Cr
Median 8 companies₹2,048.6037.20₹1,25,337 Cr7.190.70%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
73
Strong
Returns, margins, earnings quality 22% weight
Valuation
74
Strong
Cheap vs sector & own history 24% weight
Growth
7
Poor
Sales & profit trajectory 9% weight
Financial Health
76
Strong
Solvency, leverage, coverage 9% weight
Momentum
35
Poor
Trend strength, vol-adjusted 12% weight
Ownership
42
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 47.8%
  • Company has been maintaining a healthy dividend payout of 71.8%

Weaknesses

2
  • Stock is trading at 7.95 times its book value
  • The company has delivered a poor sales growth of -8.74% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish5212
OscillatorsBearish423
Moving AveragesStrong Bullish109

Key readings

RSI (14)
72.47
Bearish
MACD (12,26,9)
70.68
Bullish
SMA (50)
3,081.65
Bullish
SMA (200)
3,406.79
Bullish

As of

Analyst Rating

Based on 3 analysts
BUY67%

2 of 3 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
2
67%
HOLD
1
33%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Dec 2025; 1Y: fiscal year to Dec 2025 against Dec 2024; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−1.76%
5Y−8.74%
3Y−12.79%
1Y−8.74%
TTM−8.88%

Net profit

Net profit growth by window
10Y+0.15%
5Y−7.31%
3Y−19.25%
1Y−21.01%
TTM−10.47%

Operating cash flow

Operating cash flow growth by window
10Y+7.48%
5Y−6.44%
3Y+3.16%
1Y−5.19%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+9.58 pp
5Y+2.06 pp
3Y+1.31 pp
1Y+2.34 pp
TTM+1.21 pp

Revenue by year

Revenue by year, ₹ crore
Dec 2016₹2,367 Cr
Dec 2017₹2,460 Cr
Dec 2018₹2,771 Cr
Dec 2019₹3,071 Cr
Dec 2020₹2,902 Cr
Dec 2021₹2,957 Cr
Dec 2022₹2,770 Cr
Dec 2023₹2,851 Cr
Dec 2024₹2,013 Cr
Dec 2025₹1,837 Cr

Net profit by year

Net profit by year, ₹ crore
Dec 2016₹304 Cr
Dec 2017₹326 Cr
Dec 2018₹381 Cr
Dec 2019₹414 Cr
Dec 2020₹478 Cr
Dec 2021₹944 Cr
Dec 2022₹621 Cr
Dec 2023₹603 Cr
Dec 2024₹414 Cr
Dec 2025₹327 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹123 Cr −26.5% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk high

Sanofi India Ltd is a debt-free MNC pharmaceutical company with a market cap of Rs 7,619 crore, trading at a PE of 25x and 10.35x book value. The company has delivered strong ROE of 43-48% in recent years but faces persistent revenue decline with compounded sales shrinking at -13% TTM and -9% over five years, while maintaining a dividend yield of 2.23%.

Bull Case 7
  • Company is virtually debt-free, providing financial resilience and flexibility in a challenging operating environment
  • Exceptional return on equity at 43% last year and 48% on a 3-year basis, indicating highly efficient capital utilization despite revenue headwinds
  • Healthy dividend payout ratio of 71.8% with a current dividend yield of 2.23%, offering tangible cash returns to shareholders
  • 5-year ROE of 37% and 10-year ROE of 26% demonstrate sustained long-term profitability well above cost of equity
  • MNC parentage (Sanofi SA) provides access to global R&D pipeline, quality standards, and established brand portfolio in Indian healthcare
  • PE ratio of 25x is relatively moderate for a debt-free MNC pharma company with 40%+ ROE, suggesting valuation is not extreme on an earnings basis
  • 10-year compounded profit growth of 3% shows the company has managed to maintain profitability over the long term despite top-line challenges
Bear Case 7
  • Compounded sales have declined at -13% over the trailing twelve months, indicating accelerating revenue erosion
  • 5-year compounded sales growth of -8.74% reflects a structural and persistent inability to grow the top line
  • Stock price has declined 42% over the past 1 year, reflecting significant market de-rating and negative sentiment
  • 3-year stock CAGR of -8% and 5-year CAGR of -8% show prolonged wealth destruction for shareholders
  • TTM compounded profit decline of -13% indicates that margin management is no longer fully offsetting revenue shrinkage
  • 10-year stock CAGR of only 2% shows the company has barely kept pace with inflation over a decade, underperforming broader indices significantly
  • 3-year compounded sales decline of -13% suggests the revenue deterioration is not a one-off event but a sustained multi-year trend

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

94d ago

TL;DR: Sanofi India faces near-term leadership churn with both its CFO and a senior management head exiting by Q3 2026, though both are internal Sanofi group transitions rather than adversarial departures. No operational or financial negatives have surfaced, and Q2FY27 results due August 5 will provide the next fundamental data point. The risk is execution continuity during the leadership transition period; the trend is neutral pending earnings clarity.

Headwinds 2
  • CFO resigns effective Sep 2026 Jul 23

    Rachid Ayari resigned as Whole Time Director, CFO, and Key Managerial Personnel effective September 30, 2026. Replacement identification is still in process, creating near-term leadership uncertainty.

  • Senior management personnel exits Jul 31

    Nakul Verma will cease to be Senior Management Personnel on July 31, 2026, transitioning to another Sanofi group role. Combined with the CFO departure, two key executives are leaving within months.

Neutral 2
  • Q2FY27 earnings call Aug 5 Jul 23

    Sanofi India will hold an investor call on August 5, 2026, to discuss unaudited financial results for the quarter and half year ended June 30, 2026.

  • Nakul Verma internal transition Jul 31

    Verma's exit is an internal group transfer rather than a departure from the broader Sanofi organization, disclosed under SEBI Regulation 30.

Quarterly Results

₹ Cr
SANOFI quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
515
491
469
511
464
524
515
536
406
475
420
472
438
492
Expenses
393
377
370
374
348
404
397
364
311
341
330
330
322
331
Operating Profit
122
114
100
137
116
120
118
172
95
134
90
143
115
161
OPM %
24%
23%
21%
27%
25%
23%
23%
32%
23%
28%
22%
30%
26%
33%
Other Income
57
82
77
41
21
2
14
3
9
−22
3
4
6
6
Interest
1
0
0
0
0
0
0
0
0
0
1
0
0
0
Depreciation
9.8
9.88
10.2
10
9
9
10
10
9
9
10
9
9
9
PBT
169
186
167
169
127
113
122
165
94
102
83
138
112
158
Tax %
27%
18%
18%
19%
19%
27%
25%
28%
26%
26%
26%
26%
26%
26%
Net Profit
123
152
138
137
103
82
91
120
70
76
62
103
84
117
EPS (₹)
53.43
66.17
59.87
59.39
44.96
35.74
39.7
51.96
30.22
33.04
26.83
44.61
36.3
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SANOFI profit and loss, annual, ₹ crore
Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025TTM
Sales
1,977
2,193
2,367
2,460
2,771
3,071
2,902
2,957
2,770
2,851
2,013
1,837
1,805
Expenses
1,639
1,817
1,832
1,921
2,146
2,403
2,186
2,194
2,066
2,047
1,522
1,346
1,323
Operating Profit
339
376
535
538
625
667
716
762
704
804
491
491
483
OPM %
17%
17%
23%
22%
23%
22%
25%
26%
25%
28%
24%
27%
27%
Other Income
131
218
66
79
88
33
45
564
204
83
79
−8
−9
Interest
0
0
2
1
1
0
2
2
2
2
2
2
2
Depreciation
97
113
119
102
103
100
82
67
42
40
37
37
36
PBT
373
481
480
515
610
600
677
1,258
864
846
531
445
436
Tax %
29%
33%
37%
37%
38%
31%
29%
25%
28%
29%
22%
27%
—
Net Profit
264
322
304
326
381
414
478
944
621
603
414
327
324
EPS (₹)
115
140
132
142
165
180
208
411
270
262
180
142
141
Div. Payout %
39%
46%
51%
50%
51%
194%
176%
119%
211%
64%
65%
87%
—

Balance Sheet

₹ Cr
SANOFI balance sheet, annual, ₹ crore
Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Equity Capital
23
23
23
23
23
23
23
23
23
23
23
23
23
Reserves
1,463
1,604
1,860
2,003
2,196
2,419
2,096
2,203
1,253
992
838
726
803
Borrowings
0
0
0
0
0
0
23
25
24
19
19
18
15
Other Liabilities
742
778
658
751
765
802
777
811
772
681
732
488
567
Total Liabilities
2,228
2,405
2,541
2,778
2,984
3,244
2,918
3,061
2,072
1,715
1,612
1,255
1,407
Fixed Assets
648
877
817
769
733
499
464
334
306
315
312
304
291
CWIP
210
22
34
30
21
17
10
13
24
16
18
12
19
Investments
0
0
0
0
0
0
0
0
0
2
0
0
0
Other Assets
1,369
1,505
1,690
1,978
2,230
2,728
2,444
2,714
1,743
1,382
1,281
939
1,098
Total Assets
2,228
2,405
2,541
2,778
2,984
3,244
2,918
3,061
2,072
1,715
1,612
1,255
1,407

Cash Flow

₹ Cr
SANOFI cash flow, annual, ₹ crore
Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating
265
213
322
435
374
412
611
559
399
231
462
438
Investing
61
36
−155
−79
−73
66
276
631
651
36
−178
−11
Financing
−122
−147
−180
−188
−197
−183
−810
−849
−1,583
−878
−392
−448
Net Cash Flow
205
102
−13
168
104
295
78
341
−533
−612
−109
−21
Free Cash Flow
247
184
253
379
317
337
810
574
412
221
426
413
CFO/EBITDA
114
93
101
118
99
96
112
111
94
59
114
111

Ratios

SANOFI financial ratios, annual
Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Debtor Days
21
24
22
29
21
27
19
18
17
17
42
35
Inventory Days
179
173
169
151
154
127
107
110
125
202
186
127
Days Payable
122
81
79
119
110
100
93
105
109
89
151
79
Cash Conversion Cycle
78
115
112
61
65
54
33
22
33
130
77
83
Working Capital Days
26
9
79
17
18
35
−8
−20
−19
24
17
7
ROCE %
22%
26%
27%
26%
29%
28%
32%
35%
41%
71%
49%
58%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sanofi insights

66 extracted metrics across FY11–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 60.40%
  • DIIs 19.41%
  • Public 11.92%
  • FIIs 5.73%
  • Others 2.54%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Sanofi India

What does Sanofi India Ltd do?
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.
Where is Sanofi India Ltd (SANOFI) listed?
Sanofi India Ltd trades as SANOFI on the NSE and under code 500674 on the BSE.
Which sector does Sanofi India Ltd belong to?
Sanofi India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sanofi India Ltd?
Sanofi India Ltd trades at a PE ratio of 24.51 as of 4 Nov 2026, on earnings per share of ₹140.78, against a book value of ₹358.68 per share.
What is the 52-week high and low of Sanofi India Ltd?
Over the last 52 weeks Sanofi India Ltd has traded between ₹2,758.2 and ₹4,775 as of 4 Nov 2026.
Does Sanofi India Ltd pay dividends?
Sanofi India Ltd has a dividend yield of 2.22%.
What is the Return on Equity (ROE) of Sanofi India Ltd?
Sanofi India Ltd reported a return on equity of 43.00%. Its debt-to-equity ratio is 0.02.

Company Information

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.

Website sanofiindialtd.com
CEO Mr. Rachid Ayari
Employees 1,225
Listed 19 May 2003
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SANOFI.md for Sanofi India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month